Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company advancing precision therapies for genetically defined cancers. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's innovative pipeline, including its lead menin inhibitor ziftomenib for acute myeloid leukemia (AML).
Access authoritative updates on clinical trial progress, regulatory milestones, and strategic collaborations. Our curated collection features official press releases, financial disclosures, and scientific presentations - all organized for efficient tracking of Kura's developments in targeted cancer treatment.
Key content categories include clinical trial results, FDA communications, research partnerships, and quarterly financial reports. The repository serves as a reliable resource for understanding Kura's position in precision oncology and its approach to addressing high-need cancer populations.
Bookmark this page for direct access to Kura Oncology's verified announcements. For comprehensive analysis of these developments, consult your financial advisor and review SEC filings in conjunction with these updates.
Kura Oncology, Inc. (Nasdaq: KURA) announced its participation in the Credit Suisse 30th Annual Healthcare Conference. The event features a virtual fireside chat with CEO Troy Wilson on November 9, 2021, at 3:30 p.m. ET. Investors can access a live audio webcast on Kura's website, with a replay available afterward. Kura specializes in precision medicines for cancer, focusing on small molecule drug candidates. Key programs include KO-539 for relapsed/refractory AML and Tipifarnib for HRAS mutant head and neck cancer, highlighting the company's innovative approach to oncology.
Kura Oncology, Inc. (Nasdaq: KURA) will release its third quarter 2021 financial results on November 4, 2021, after U.S. markets close. A webcast and conference call, scheduled for 4:30 p.m. ET / 1:30 p.m. PT, will provide financial insights and a corporate update. The call can be accessed by domestic and international callers with specific dial-in information. Kura focuses on innovative cancer treatments, including KO-539 for AML and Tipifarnib for HRAS mutant HNSCC, highlighting its commitment to precision medicine.
Kura Oncology (Nasdaq: KURA) has appointed Teresa Bair as Chief Legal Officer and Corporate Secretary. Bair brings over 25 years of legal experience, recently serving as General Counsel at Athenex, where she assisted in multiple NDA filings and an FDA approval. Kura's President, Troy Wilson, emphasized her expertise in drug development, crucial for advancing their oncology drug pipeline. Kura focuses on precision medicines for cancer, with pipeline candidates like KO-539 and tipifarnib, which has gained Breakthrough Therapy Designation.
Kura Oncology (Nasdaq: KURA) announced that Troy Wilson, Ph.D., J.D., CEO, will participate in two virtual investor conferences. He will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with an on-demand recording available starting at 7:00 a.m. ET. Additionally, he will engage in a fireside chat at the Cantor Global Healthcare Conference on September 27, 2021, at 3:20 p.m. ET. Audio webcasts of both events will be accessible on Kura's website, with archived replays available after both events.
Kura Oncology reported its Q2 2021 results, highlighting key advancements in clinical trials and collaborations. The first patients have been dosed in the Phase 1b cohorts for KO-539, a menin inhibitor targeting relapsed/refractory AML. A collaboration with Novartis aims to assess tipifarnib with alpelisib in HNSCC. Kura has also nominated KO-2806 as its lead candidate in a new farnesyl transferase program. Financially, the company reported a net loss of $33.7 million with $567.5 million in cash reserves expected to sustain operations into 2024.
Kura Oncology, Inc. (Nasdaq: KURA) announced its participation in the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021. CEO Troy Wilson will join a panel discussion titled “Bullseye - Targeted Oncology Part 2” at 10:20 a.m. ET. A live audio webcast will be accessible via the Investors section of Kura's website, with a replay available shortly after the event. Kura focuses on precision medicines for cancer, currently advancing drug candidates like KO-539 and Tipifarnib in clinical trials targeting specific cancer types.
Kura Oncology, a clinical-stage biopharmaceutical company, will announce its second quarter 2021 financial results on August 5, 2021, after market close. A webcast and conference call will follow at 4:30 p.m. ET. The company is focused on precision medicines for cancer treatment, with several drug candidates including KO-539 for acute myeloid leukemia and tipifarnib for HRAS mutant head and neck squamous cell carcinoma. Kura's therapies aim to target specific cancer pathways and improve patient outcomes.
Kura Oncology, Inc. (Nasdaq: KURA) announced the appointment of Dr. Helen Collins to its board of directors. Dr. Collins, a veteran in medical oncology with over 25 years of experience, previously served as Chief Medical Officer at Five Prime Therapeutics. Her expertise will be instrumental as Kura advances its pipeline, including the KO-539 menin inhibitor in acute myeloid leukemia and the tipifarnib program for HRAS mutant head and neck squamous cell carcinoma. This strategic addition aims to enhance Kura's clinical development efforts and fulfill its mission of precision cancer therapies.
Kura Oncology, Inc. announced a clinical collaboration with Novartis to study the combination of tipifarnib and alpelisib for treating head and neck squamous cell carcinoma (HNSCC) driven by HRAS or PIK3CA pathways. This follows promising preclinical results indicating enhanced anti-tumor activity when both drugs target co-dependent pathways. The Phase 1/2 KURRENT trial is set to commence in the second half of 2021, aiming to potentially broaden tipifarnib's application among advanced HNSCC patients. Kura retains global rights to tipifarnib.
Kura Oncology announced the dosing of the first patient in the Phase 1b expansion of KOMET-001, targeting relapsed/refractory acute myeloid leukemia (AML) with its selective menin inhibitor, KO-539. The trial includes two cohorts: 200 mg and 600 mg doses, each enrolling at least 12 genetically enriched patients. KO-539 showed promising activity and a favorable safety profile in prior phases. The data obtained will aid in determining the recommended Phase 2 dose and potentially contribute to registration efforts. Kura aims to present future data at medical meetings.
